Profil

Pilard Charlotte

Main Referenced Co-authors
Herfs, Michael  (25)
Hubert, Pascale  (25)
Delvenne, Philippe  (24)
Hendrick, Elodie  (24)
Roncarati, Patrick  (24)
Main Referenced Keywords
HPV (3); Cancer (2); Biochemistry, Genetics and Molecular Biology (all) (1); Chemistry (all) (1); DNA damage and repair (1);
Main Referenced Unit & Research Centers
Giga-Cancer - ULiège [BE] (3)
Main Referenced Disciplines
Oncology (26)
Microbiology (1)

Publications (total 27)

The most downloaded
77 downloads
Lebeau, A.* , Bruyère, D.* , RONCARATI, P., Peixoto, P., Hervouet, E., COBRAIVILLE, G., Taminiau, B., Masson, M., Gallego, C., Mazzucchelli, G., Smargiasso, N., Fleron, M., Baiwir, D., Hendrick, E., Pilard, C., Lerho, T., Reynders, C., Ancion, M., GREIMERS, R., ... Herfs, M. (28 February 2022). HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nature Communications, 13 (1), 1076. doi:10.1038/s41467-022-28724-8 https://hdl.handle.net/2268/288940

The most cited

81 citations (Scopus®)

Hubert, P., RONCARATI, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., Meunier, M., Nokin, M.-J., Hendrick, E., Peulen, O., Delvenne, P., & Herfs, M. (2021). Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for ImmunoTherapy of Cancer, 9 ((3)), 001966. doi:10.1136/jitc-2020-001966 https://hdl.handle.net/2268/258085

Ancion, M., Luyckx, M., Renard, M., Reynders, C., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., Herfs, M., & Hubert, P. (12 June 2023). Approach using "second generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer [Poster presentation]. EACR 2023, Turin, Italy.

Bruyere, D., RONCARATI, P., Lebeau, A., Lerho, T., Poulain, F., Hendrick, E., Pilard, C., Reynders, C., Ancion, M., Luyckx, M., Renard, M., Jacob, Y., Twizere, J.-C., Peiffer, R., Peulen, O., Delvenne, P., Hubert, P., McBride, A., Gillet, N., ... Herfs, M. (2023). Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. Theranostics, 13 (3), 1130 - 1149. doi:10.7150/thno.78091
Peer Reviewed verified by ORBi

Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (09 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Poster presentation]. INTERUNIVERSITY PHD STUDENT DAY.

Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Hendrick, E., Bruyère, D., Delvenne, P., Hubert, P., & Herfs, M. (06 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV infections in carcinogenesis [Poster presentation]. GIGA-Day 2022.

Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., Delvenne, P., Hubert, P., & Herfs, M. (29 April 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Paper presentation]. Séminaire du GIGA-Cancer, Belgium.

Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Hendrick, E., Bruyère, D., Pilard, C., Delvenne, P., Hubert, P., & Herfs, M. (08 April 2022). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Séminaire des chercheurs Télévie 2022, Belgium.

Lebeau, A.* , Bruyère, D.* , RONCARATI, P., Peixoto, P., Hervouet, E., COBRAIVILLE, G., Taminiau, B., Masson, M., Gallego, C., Mazzucchelli, G., Smargiasso, N., Fleron, M., Baiwir, D., Hendrick, E., Pilard, C., Lerho, T., Reynders, C., Ancion, M., GREIMERS, R., ... Herfs, M. (28 February 2022). HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nature Communications, 13 (1), 1076. doi:10.1038/s41467-022-28724-8
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (14 December 2021). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Giga Cancer Day 2021.

Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., Hubert, P., Delvenne, P., & Herfs, M. (01 October 2021). Caractérisation histopathologique des cancers œsophagiens et potentiel rôle des HPV [Paper presentation]. Conférence annuelle de l'Association Francophone pour l'étude des Infections à Papillomavirus et Polyomavirus, France.

Pilard, C. (01 April 2021). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Paper presentation]. Télévie Webinar.

Bruyère, D., Monnien, F., Colpart, P., RONCARATI, P., Vuitton, L., Hendrick, E., Lepinoy, A., Luquain, A., Pilard, C., Lerho, T., Molimard, C., Maingon, P., Arnould, L., Bone-Lepinoy, M.-C., Dusserre, L., Martin, L., Reynders, C., Ancion, M., Peiffert, D., ... Herfs, M. (2021). Treatment algorithm and prognostic factors for patients with stage I–III carcinoma of the anal canal: a 20-year multicenter study. Modern Pathology, 34, 116-130. doi:10.1038/s41379-020-0637-6
Peer Reviewed verified by ORBi

Pilard, C.* , Ancion, M.* , Delvenne, P., JERUSALEM, G., Hubert, P., & Herfs, M. (2021). Cancer immunotherapy: it’s time to better predict patients’ response. British Journal of Cancer, 125(7), 927-938. doi:10.1038/s41416-021-01413-x
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Hubert, P., RONCARATI, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., Meunier, M., Nokin, M.-J., Hendrick, E., Peulen, O., Delvenne, P., & Herfs, M. (2021). Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for ImmunoTherapy of Cancer, 9 ((3)), 001966. doi:10.1136/jitc-2020-001966
Peer Reviewed verified by ORBi

Pilard, C. (11 December 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Paper presentation]. GIGA-Cancer seminar.

Pilard, C., RONCARATI, P., Hendrick, E., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (03 November 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Paper presentation]. Cytokines 2020, Seattle (Virtual), United States.

Pilard, C., RONCARATI, P., Hendrick, E., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (03 October 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. 7th Immunotherapy of Cancer Conference (ITOC7), Munich (Virtual), Germany.

Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (01 October 2020). P08.03 Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy. Journal for ImmunoTherapy of Cancer, 8 (Suppl 2), 50-A51. doi:10.1136/jitc-2020-ITOC7.99

Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (07 February 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. BACR 2020, Jette, Belgium.

Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (29 January 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. Télévie Seminar 2020, Bruxelles, Belgium.

Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (21 May 2019). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. Immunology Day 2019, Liège, Belgium.

Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (01 February 2019). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. BACR 2019, Anvers, Belgium.

Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (28 January 2019). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. Télévie Seminar 2019, Gembloux, Belgium.

Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (13 September 2018). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. GIGA-Cancer Day 2018, Liège, Belgium.

Bruyère, D., Lebeau, A., RONCARATI, P., Hendrick, E., Masson, M., Twizere, J.-C., Pilard, C., Hubert, P., DELVENNE, P., & Herfs, M. (30 May 2018). Deciphering the radiosensitivity of HPV-positive tumors [Poster presentation]. 5th meeting on emerging issues in oncogenic virus research, San Pietro in Bevagna, Italy.

Bruyère, D., Lebeau, A., RONCARATI, P., Hendrick, E., Masson, M., Twizere, J.-C., Pilard, C., Hubert, P., DELVENNE, P., & Herfs, M. (28 May 2018). Deciphering the radiosensitivity of HPV-positive tumors [Poster presentation]. EDT-Immunology day 2018, Liège, Belgium.

Lebeau, A., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., TAZIAUX, S., Hubert, P., Delvenne, P., & Herfs, M. (28 May 2018). HPV-related innate peptide inhibition promotes the acquisition of bacterial/fungal infections within the genital tract [Poster presentation]. Immunology day 2018, Liège, Belgium.

Lebeau, A., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., TAZIAUX, S., Hubert, P., Delvenne, P., & Herfs, M. (01 February 2018). HPV-related innate peptide inhibition promotes the acquisition of bacterial/fungal infections within the genital tract [Poster presentation]. Annual Televie seminar, Bruxelles, Belgium.

Contact ORBi